RecruitingNCT03966443
Fluciclovine PET/CT in Multiple Myeloma Patients
PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Sponsor
Oslo University Hospital
Enrollment
10 participants
Start Date
Mar 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether a special PET scan using a tracer called fluciclovine (18F-fluciclovine) can better detect and locate multiple myeloma tumors in the body compared to standard imaging. The scan is done before and after a stem cell transplant (autologous SCT) to see how well it tracks treatment response.
**You may be eligible if...**
- You have multiple myeloma and are eligible for an autologous stem cell transplant (a transplant using your own stem cells)
- You are willing to undergo the PET/CT imaging scans as required by the study protocol
**You may NOT be eligible if...**
- You have a condition or reason that makes you ineligible for an autologous stem cell transplant
- You are unable or unwilling to consent to the imaging scans
- You are pregnant or breastfeeding
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03966443